Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Medivir, Audiocast, Q1'26

By Inderes5/5/2026, 12:00 PM
Medivir

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jens Lindberg
00:00 - 06:02

Thank you. Operator. Welcome, everyone, to the Medivir Q1 2026 results webcast. And we look back at a transformative quarter where we strengthened our financial position. We've opened up a new rare disease opportunity with MIV-711, and we just came back from a successful and quite invigorating trip to Korea, where we visited a number of the highly engaged hospitals and investigators now eager to get going in the FLEX-HCC study. And I will share more on that particular topic in just a little bit. And we've also seen our partner, Vetbiolix in France, make great progress in the past quarter. So we are looking ahead to the remainder of 2026 with great anticipation. As mentioned. So that we are. So we've just come back from Korea and the interest in the FLEX-HCC study is very strong among the hospitals. And the interest to participate in the study is quite high. So the Korean Cancer Study Group, they have added four additional hospitals in the quarter. And the interest as we were visiting them was quite palpable when we had the opportunity to meet with eight of the hospitals face to face. We also understand, however, that perhaps the greatest interest in the study is when it is starting? And we're happy to be able to convey today that we've just received news that the first two sites are now open to start enrolling patients. So our trip to Korea came at a perfect time. We were able to engage with them just as the study is about to open and they're about to start enrolling patients. We have also spent quite a bit of time in the last quarter engaging externally with clinical and regulatory experts, as well as patient organizations in the field of Osteogenesis Imperfecta to confirm and finalize study design plans for the proof-of-concept study in the disease. And we have been positively surprised by the great interest and willingness to engage across all the stakeholders. And perhaps most importantly, while some of those interactions have led to adjustments in our plans, the overall plan remains firm, and our belief in the potential of MIV-711 has been strengthened. MIV-711. In Osteogenesis Imperfecta. And then finally, as I mentioned, our partner, Vetbiolix, continues to rapidly progress their clinical efforts with MIV-701 or as they call it, VBX-1000, for periodontal disease in dogs. And as of end of April, they have now recruited more than 40% of the subjects in the. In their ongoing study to confirm that MIV-701 has the opportunity to be the first disease modifying treatment for the disease, which is a critical step to unlock the blockbuster potential of the drug. They. And they expect results in Q4 this year. And that will be a significant potential inflection point for the program and also for us. Of course. Today we will focus on those. So these are our programs, as you can see. So the in-house programs at the top Fostrox for liver cancer and MIV-711 for Osteogenesis Imperfecta. We will touch more on those two programs today and the progress we've made. And we'll also touch on the out-licensed program to Vetbiolix. Hence, those marked in green. One minor comment to make regarding one of the other programs, and that is Remetinostat, is that following on from us making the agreement with Biossil last year, the Gorlin Syndrome Alliance, which is a not-for-profit organization in the US, supporting patients, families, and healthcare providers, has actively reached out to us and then to Biossil, eager, as they heard the news, to support the development in patients specifically with Gorlin syndrome, a genetically driven disease. And that manifests predominantly as patients get multiple BCC lesions, where surgery is many times not a good option. So for them, development of Remetinostat in that particular rare disease subpopulation is critical. And that's also our understanding from discussions with Biossil as they licensed the drug, that that might well be their first development path. So interesting. It's interesting to see interest in that drug as well. And we look forward to hearing more about their plans as we move forward. Today, I am joined by our CMO, Pia Baumann, our new CFO, Patrik Norgren, who joined us just a month back. And then our CSO, Fredrik Öberg. But with that said, let me hand over to Pia to share an update on our efforts with both Fostrox as well as MIV-711, including then our recent engagements on the ground in Korea. So Pia, over to you.

Pia Baumann
06:03 - 11:48

Thank you, Jens, and thanks for the introduction. Also about what has been going on when it comes to Fostrox. But just as a reminder, the FLEX-HCC study that is the reason why we went to Korea is a randomized, second line study in liver cancer. And it's really there to strengthen the evidence that we have from our single arm trial with Fostrox plus Lenvima in liver cancer, and to show superiority over Lenvima alone. So just as a reminder, what this study is, is that Fostrox is combined with Lenvima in one arm, and it's randomized against Lenvima monotherapy in the other arm, and 80 patients will be enrolled in this study, who have progressed or are intolerant to prior immunotherapy combinations. And as Jens said, the patients will now be enrolled at 12 sites instead of the original eight sites, due to high interest. And the PI for the study is Professor Hong Jae Chon from CHA Bundang Hospital, and he is doing this study in close collaboration with the Korean Cancer Study Group, and I think that is also the reason why there is a high interest, because this group recently executed and also published, actually, the only prospective study with lenvatinib monotherapy in a similar patient population that will be enrolled in the FLEX-HCC study. So it's a really, really nice setup. And here, patient enrollment is expected to take around 12 months, and the primary endpoint will be evaluated by a blinded, independent central review to make sure that we have the quality that is required to really show this difference. And since we hope this study will enroll and perform relatively quickly, the topline results are expected already in 2027. We had the opportunity to visit eight of the 12 sites last week in Korea. And right now two of the sites are open for enrollment and that is Cha Bundang, where Professor Chon is situated, and Severance Hospital. And we know that they are super eager to have the first patient in. And as you can see on this map here, if you can see it, the site is geographically spread across Korea also to have the best chance of capturing all the patients that could be eligible for this study. And since we had the opportunity now to discuss with the investigators, it became really, really clear that there is a very high interest in participating in this study and that they have quite a few second-line patients every week that potentially could be candidates to be enrolled. Overall, the support for the study and the P.I. Professor Chon was overwhelming, and it confirms really the expertise and the quality his name is associated with when it comes to liver cancer studies. So overall, we were very welcome and they were extremely interested in Fostrox also as an alternative with another mechanism of action compared to both immunotherapy and TKI. That is usually the one that you can use in this patient population. So we can go to the next slide. So to summarize the takeaway from this visit, we can conclude that unfortunately, liver cancer continues to be a very common disease in Korea. Despite that, they now have started vaccination. It's still very common, and while there are first-line treatment options now with immune combinations, primarily, there is a high unmet need in subsequent treatment lines, particularly in the second-line setting, where many patients can tolerate second-line treatment. But still there is no optimal treatment. So the sites are fully committed to the FLEX-HCC study, and it fits very well with a standard treatment for advanced HCC. The majority, an estimated 80%, will have received it. Something like that will have received Tecentriq/Avastin, the immune combination in first line, and almost all of them are using Lenvima in the second line setting. That's why this trial really fits well in, and most of the sites had no competing studies ongoing in HCC and those who actually had studies ongoing, it was mainly cell therapy or bispecific targeting GPC-3, which I think that all of you are interested in. HCC, I've heard, has been a target that has been discussed for quite a few years now, and we are waiting for the results, but it's mainly in the first-line population and selected patients there. So the interest in Fostrox is also partly built on the fact that it is an all-comers population. You don't need to do any biomarker testing, and it could be something that is available for more patients than those are selected in the other GPC-3 trials. So high interest. We can go to the next slide, and I think I'll leave it to you.

Jens Lindberg
11:49 - 13:36

Just to summarize, first and foremost, we were highly encouraged that it's always good to meet face to face and see that engagement and commitment. Now, Bundang and Severance Hospitals are open for enrollment, with the other hospitals to follow shortly. And it feels quite good. And we're very much looking forward to the progress and, with their engagement, also looking forward to the speed of recruitment. And for everyone, to summarize again, we have the first and only liver-activated small molecule selectively targeting tumor cells in the liver, sparing healthy liver cells. And that is also clearly from some of the hospitals. We've met new physicians, discussing the drug in greater detail than previously. It is one of those areas, one of the features that they appreciate the most. And so we continue to move forward. And as I said, there has been very little development in second line, and very few competing studies. So again, our aim is to hopefully become the first approved second-line treatment in advanced HCC for a market that is conservatively evaluated at 2.5 billion USD per year. But with that and on the note of hospitals opening up, we moved to the second program. And let's talk a little bit about what has happened with MIV-711 since we last spoke here.

Pia Baumann
13:37 - 14:26

So for MIV-711, we are aiming to do a proof of concept study in Osteogenesis Imperfecta. And since we really need to have advice both from the scientific community, but also from other parts, we have first and foremost formed a Scientific Expert Council and they will provide advice and they have already provided advice. We have had our first advisory board and feedback on the development path and also on the study design. It is now, initially, for the planned proof-of-concept Phase 2 study. So, the members of this council are highly renowned global experts. I'm sorry.

Jens Lindberg
14:27 - 14:28

Go ahead.

Pia Baumann
14:29 - 21:16

Highly renowned global experts in Osteogenesis Imperfecta. And they have a background, as many of those working with OI have, an endocrinologist, internist, rheumatologist, and we also have a pediatric endocrinologist. Part of this advisory council, the Scientific Expert Council, since that is where we eventually aim and this is a genetic hereditary disease that affects patients from childhood, all of them in this council have vast experience in clinical study design, translational research, and also in pre-clinical research. And they have been part of centralizing patient treatment and care at hospitals. And they have also been part of developing systemic treatment, which we discussed last time. This includes the Anti-sclerostin treatments that have not been successful in their primary endpoint, and they have also been part of that development. So we are trying to take as much experience as possible from earlier treatment programs to understand how we are going to be successful in the initial development for OI. And obviously, their expertise and advice will be crucial to finding the optimal study design and also to find the sites where we can enroll patients and, in addition to that, provide the context of how the standard of care for these patients looks like. So the study, this is a very schematic design of the phase two randomized proof of concept study that we are showing you so far. And it is. It will enroll patients that have experienced at least one fracture during the last two years, and they will be randomized 1 to 1 into a high or low dose arm of MIV-711, which is an oral treatment. It is a once daily treatment. And we can come back to that. But this is something that is really important for the patient as well, that it is an oral treatment and not an intravenous treatment because they have seen the inside of hospitals their whole life. So this is a very positive part for them as well. The endpoints will include biomarkers of bone resorption and also measurement of bone mineral density. So this proof of concept will be built on these two, but also other endpoints will be looked at. Obviously PK, safety, and we will also evaluate the number of fractures. Even if the follow-up time will probably not be long enough in this study, it will at least give us some idea. Enrollment will be in Europe, and since these patients are already known at the sites, having been identified from childhood, we expect very fast enrollment, and we are currently working on finalizing the study design. And in addition to our Scientific Expert Council, we have contacted other important forums for advice, and these forums include some of them we see here. We are presenting regulatory and patient organizations. And first, you can see here we met a former FDA regulatory expert that is also a pediatric physician who previously worked in the clinic with OI patients. And we received advice on filing for Rare Pediatric Disease Designation. And also the next development step in both adult and pediatric OI. Since there is a need for treatment in the whole segment from pediatric to adolescent to adult, we also met with the chair of the Osteogenesis Imperfecta Federation, OIFE, to better understand the patient perspective and the general unmet need. And in addition to that, we have participated in the annual meeting for the Swedish organization for OI, where we had the opportunity to present our development plan for MIV-711 in OI, and that included also the Proof-of-Concept Phase 2 study design that we have drafted to receive insights from the patients to understand if this is feasible or not, and also to gain more knowledge. What is the most important question for them? The key takeaways were that there is a strong engagement from the external experts, with a deep scientific support for the specific mechanism of MIV-711, the anti-cathepsin K in OI. And there is a high interest in this proof-of-concept study. We also learned that the existing clinical and nonclinical package that we already have for MIV-711, together with a significant unmet need, really supports the development in a pediatric population, and that it was confirmed that there is a potential for Rare Pediatric Disease Designation with the Priority Voucher, so long as the patient organizations really emphasize the significant medical need here. And it is across all subtypes of OI. And it also includes the milder Type 1. And they really supported our plan for this proof of concept study with MIV-711. As I already said, it was more important than we probably realized before we went there that it is an oral treatment that can be taken at home without having to go to the hospital. So overall, a really, really positive meeting sequence and important advice, and I will leave it to Jens.

Jens Lindberg
21:17 - 26:44

Thank you, Pia. And I think, just to backtrack a little to the last quarterly call we had. Clearly, as a team, as we embark on this type of journey, we have done quite a bit of work on the molecule and in terms of planning, but there's always the element that as you step up your external engagements, whether with clinical or regulatory experts, and you start to deep dive, there's always the worry about how on spot we have been. So it's been super, super encouraging to see where we have aimed the plans we had. They've been highly supportive of those plans, worked with us to do some further adjustments and tweaks, but overall, we were already at that time sort of on the right path. And that has been confirmed in the interactions in the past few months, which is highly encouraging. And if we look at it from a market opportunity perspective, one other element that has been confirmed is that the estimated prevalent OI population is roughly around 7,000 patients across the US, EU, Japan, and Korea. The significant unmet medical need across all subtypes. I think that's been a key element because, despite indications sometimes suggesting that for the mild subtype one the unmet medical need isn't so big, it's super clear from both experts and patients that the milder group has a very significant unmet medical need and is in need of new treatment options as well. So confirmation overall that the market opportunity here is of similar size as we see with Fostrox in the advanced liver cancer space. So, of equal size for the second program. So all in all, as we have shown previously, the plan continues to stay the same. There are no treatment options available, particularly after Ultragenyx's failure in phase three. In quarter four. So unmet need there. The potential to be the first approved treatment option in this disease is still there, and we are eagerly looking forward to embark on the Phase 2 Proof-of-Concept study. So with that, just to take a few words as we continue to see progress with Vetbiolix as they are moving forward. And since the last study, they've continued to enroll subjects or dogs. So more than 40%. And so far, we eagerly look forward to the results in quarter four. To refresh our memory on what the drug does and what it targets: VBX-1000, for periodontal disease, is in development for stage two and stage three, i.e. before the need for surgical removal of the teeth. And it is the first disease modifying treatment in development for periodontal disease, and as such, has the potential to prevent significant suffering as well as very costly procedures, such as removing the teeth if the disease progresses too far. And as a disease modifying treatment, if successful, it clearly has the potential to transform how these dogs are treated moving forward. The study remains unchanged from what we showed last time, with 22 of the 51 targeted dogs already enrolled by the end of April. From a financial, commercial potential perspective, as a company, our upside potential lies in royalty revenues and any sort of share of potential Vetbiolix partnership payments. And with more than 70 million dogs in the US and EU suffering from periodontal disease, the commercial potential is clearly significant. In our estimations, if the program has a positive outcome and gets to market as a disease-modifying treatment, we estimate the potential for us through annual royalty revenues of approximately 700 million SEK per year. After five years post-launch, as per the agreement with Vetbiolix, the financial terms are focused on upside upon approval and commercialization. So with that, I hand over to Patrik for the financial details before we go to Q&A.

Patrik Norgren
26:44 - 28:00

Let's go to slide 22. And I will present the financial summary for Q1. And all the numbers are in million SEK. As you can see, the net turnover for Q1 was 1 million, which was 0.4 million higher than Q1 last year. And other external expenses were 4.5 million, and the personnel cost was 5.5 million. And in total, the total operating costs were 10 million, which is 3.5 million lower than Q1 last year. It is mainly related to fewer employees and lower costs for clinical studies. The operating loss was -9.4 million, which is almost 4 million better than last year. Q1 2025. The cash flow from operating activities was -13 million, and Medivir has a strong cash position. The cash balance for end of Q1 was 149.1 million SEK. Okay.

Jens Lindberg
28:01 - 28:12

So with that, thank you, everyone for listening to the presentation part of the webcast. And, operator, we can now open up for Q&A.

Operator
28:13 - 28:30

If you wish to ask a question, please dial Pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Richard Romanius from Redeye. Please go ahead.

Richard Romanius
28:33 - 28:43

Good afternoon. I have a few questions. The first one is when exactly do you expect to dose the first patient in the Fostrox study?

Jens Lindberg
28:46 - 28:47

Do you want to take it or should I take it?

Pia Baumann
28:48 - 29:03

So, two sites are open, and obviously we are hoping that will happen soon, as eager as they are to enroll patients. But I cannot say. But any day now, I would say.

Jens Lindberg
29:05 - 29:21

I think that we've clearly prepared for it. Drug is on site in Korea as well. As they open the sites for enrollment, they are now ready to start including and initiating patients.

Richard Romanius
29:24 - 29:42

Okay. I was also thinking about the study in Osteogenesis Imperfecta. What age group do you think you will target in the study design and what type of disease?

Pia Baumann
29:44 - 30:10

Yes. So this is still a draft, but I can say that we are aiming for an adult population in this first proof of concept study. And to find a relatively homogeneous population, probably the milder ones. But we will come back when we have a more firm study design and when we have received all the feedback that we need.

Richard Romanius
30:13 - 30:22

All right. When do you think VBX-1000 could be on the market? At the earliest.

Jens Lindberg
30:24 - 31:57

I think it's a bit difficult for us to speculate on. And I think that I would defer that sort of topic more to the animal health experts, with regard to Vetbiolix in particular. And we've had discussions with the Vetbiolix team to see whether we should organize as we progress. And as the study starts for Fostrox, as we progress our plans and we firm up our plans on OI, we would also look to have a capital markets day where we would include the Vetbiolix team, and I think that might be a better suited topic for answering that question in a bit more detail, but what I can say in terms of what they've communicated, they anticipate the readout of this study, which is an important one. And that will be a key inflection point for them. But they are also anticipating either themselves or a partner, which wouldn't be surprising if they moved to an outlicensing situation after this study. There is an anticipation of a registrational study, as well as the next step, before final approval and timing of that, I would be a bit difficult for me to speculate on, but it seems relatively clear that as they run studies, they are able to recruit subjects quite quickly.

Richard Romanius
31:59 - 32:02

Okay. Very good. Thanks for answering my questions.

Operator
32:05 - 32:18

As a reminder, if you wish to ask a question, please dial pound five on your telephone keypad. The next question comes from Klaus Palin from DNB Carnegie. Please go ahead.

Klaus Palin
32:20 - 32:45

Thank you, and thanks for taking my question. We'll start with that. Fostrox question. Nice to hear that. You now have two sites open in Korea, but just a little bit curious why expanding the number of sites from 8 to 12? Is this purely driven by interest or anything else?

Pia Baumann
32:47 - 33:24

So, this is a collaboration with the Korean Study Group, which is a national study group that just performed another study where they had actually 13 sites enrolled. I would assume that there was such high interest that it's a little bit difficult to maybe select those because all of them enrolled patients. Right. So, and all of them are qualified and they are in different parts of Korea. So, it is of interest. They have expanded the sites, not that they are worried that they wouldn't enroll fast enough.

Klaus Palin
33:27 - 33:32

Okay. And you're sticking to the timeline that you have previously announced.

Pia Baumann
33:32 - 34:04

Yes. And I would say, we can just see how the environment looks when we are at the sites. But it was encouraging to see how many second-line patients they have. Then, of course, we can never know if they are eligible or not, since they are also a heterogeneous population in HCC. But it's very encouraging to see how many patients they have at these sites we visited. And so I'm not worried about the timelines.

Jens Lindberg
34:04 - 35:12

I think the added comment clause is sort of the. And I think, as Pia is alluding to, that the decision to include four additional sites was a Korean Cancer Study Group decision. That wasn't a push from us with regards to speeding up timelines. That came from them. We have an agreement, and that agreement was for eight sites and there's a budget for eight sites, etc. This came from them, and this is a decision that they took. And it doesn't add any budgetary costs for us. . So it purely reflects their engagement and the interest from their hospitals that they felt that they wanted to include them. So for us, we only see this as a pure positive. It can only speed up recruitment. But that said. Rather than promising a quicker recruitment, we're sticking with the timelines. But hopefully, some of this can help. This can contribute to recruiting even faster.

Klaus Palin
35:14 - 35:49

Okay, perfect. And my next question is then related to Osteogenesis Imperfecta. And it relates to your interactions with experts. If you had a chance to discuss a potential primary endpoint for a pivotal study and also perhaps discuss the development that has been seen in osteoporosis, where bone mineral density has emerged as a surrogate endpoint.

Pia Baumann
35:50 - 38:35

Thank you. It's a very good question. And yes, we have the possibility to discuss it with them. But remember, this is the first study we are doing, a Proof-of-Concept study. And bone mineral density is what you can use for that study together with other biomarkers for bone resorption. So to see that our hypothesis holds. And when it comes to the primary endpoint for a pivotal study, it is of huge interest also for the whole OI community and for everyone who is developing anything in this disease. Since the FDA has required previously to look at annual fracture rate. And we talked about this before, Ultragenyx's study was not positive when it came to annual fracture rate. So this is something that is concerning, obviously, for the OI community since they want to have an approved drug. So this is a discussion that I know is going on with the regulatory authorities, also with the OI community, but so far I haven't heard what that endpoint could be. If annual fracture rate is not the primary endpoint, what about bone mineral density? It is an approved endpoint in osteoporosis, and I think we have said that before as well. You could potentially consider OI, particularly in the adult population, as osteoporosis on steroids. So, and with the same amount of bone mineral density loss. So I think, depending on data you can also show in the future where you can validate bone mineral density against fracture rate. I think that is going to be important. And the collective new data will potentially contribute to, I don't know if it's ever going to be a surrogate endpoint for OI, but it is a good endpoint for showing proof of concept. But it has also been shown that, for example, with bisphosphonates, even if bone mineral density is increased, a reduction in the fracture rate has not been demonstrated. And I think that is sort of the base for not having this endpoint accepted in OI. But if you can show that you still have bone remodeling, which we hope to show with MIV-711, and you actually can see that you are at least having some kind of effect on fracture rate, maybe it will be a possibility in the future.

Klaus Palin
38:36 - 38:41

Okay. Okay. Thank you so much. That was all for me.

Operator
38:45 - 38:51

There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.

Jens Lindberg
38:53 - 40:49

Thank you. And before we close the call, we want to reiterate that we are very encouraged by the engagement in the FLEX-HCC study among the investigators. And the hospitals' usual standard approach is for us to communicate via a press release when we have the first patient dosed in a study, and we are eagerly looking forward to that as we have the quarterly call today, and we just gotten the news that we now have two hospitals open to start enrolling patients, and we wanted to share that today, and we are super happy that those two first are up and running, and we have drug on site, and we look forward to, as P alluded to, also sharing the update as that first patient is dosed and randomized. But we're very happy with the progress so far. Over the past months, our belief in MIV-711 as a candidate for treatment of Osteogenesis Imperfecta has only grown stronger, and our development plans for MIV-711 have generated support from both clinical and regulatory experts, which has been very positive progress, and we are very pleased to see the progress with MIV-701, eagerly anticipating the results. Q4 this year, that event will be a significant inflection point for the program. Of course, it will be an inflection point for Vetbiolix as a company and, as a result, also for us here at Medivir. So, on that note, with the progress made and with the positive outlook to the future, we thank you for attending today's call and wish you all a great day.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…